Tonix Pharma Files Patent Complaint Over TONMYA Generic
Tonix Pharma ( ($TNXP) ) just unveiled an announcement. On October 1, 2026, Tonix Pharmaceuticals Holding Corp. received notice that Dr. Reddy’s Laboratories had filed an ANDA with the FDA
Compare Stocks
Compare up to 40 stocks
Compared Stocks: 1 / 40
Comparison Results
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 TNXP | Healthcare | $3.01 | 1.94M | $58.49M | -0.24 | ― | Strong Buy |
Top 10 Popular Investment Themes
- Quantum Computing Stocks
- Dividend Stocks
- Magnificent 7 Stocks
- Nuclear Stocks
- Oil Stocks
- Tech Stocks
- Blue Chip Stocks
- Energy Stocks
- Bank Stocks
- Gold Stocks
Popular Stock Pairs
- AAPL vs. MSFT (Apple vs. Microsoft)
- AAPL vs. NVDA (Apple vs. Nvidia)
- AMD vs. INTC (AMD vs. Intel)
- AMZN vs. GOOGL
- AMZN vs. WMT (Amazon vs. Walmart)
- AVGO vs. QCOM (Broadcom vs. Qualcomm)
- COST vs. WMT (Costco vs. Walmart)
- F vs. GM (Ford vs. General Motors)
- GOOGL vs. META (Alphabet vs. Meta)
- HD vs. LOW (Home Depot vs. Lowe's)
- JPM vs. BAC (JPMorgan vs. Bank of America)
- KO vs. PEP (Coca-Cola vs. PepsiCo
- MSFT vs. GOOGL vs. AMZN (Cloud Wars)
- NVDA vs. AMD vs. INTC (Chip Giants)
- NVDA vs. TSM (Nvidia vs. Taiwan Semi)
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TNXP | Tonix Pharma | 3.01 | -12.89 | -81.07% |
| Name | Price | % Change | |
|---|---|---|---|
| TNXP | $3.01 | -81.07% |
Custom Stock Latest News
Tonix Pharmaceuticals price target lowered to $40 from $65 at Alliance GlobalAlliance Global analyst James Molloy lowered the firm’s price target on Tonix Pharmaceuticals (TNXP) to $40 from $65 and keeps a Buy rating on the shares. The firm cites the
4d agoTNXP
AI-Driven Risk: Operational, Compliance and Data Challenges in Tonix Pharmaceuticals’ Use of Artificial IntelligenceTonix Pharmaceuticals (TNXP) has disclosed a new risk, in the Technology category. Tonix Pharmaceuticals’ reliance on AI and computational tools in research, drug development and corporate functions introduces significant operational
5d agoTNXP
Tonix Pharmaceuticals Earnings Call Highlights TONMYA GrowthTonix Pharmaceuticals (($TNXP)) has held its Q3 earnings call. Read on for the main highlights of the call. Tonix Pharmaceuticals’ earnings call struck a largely positive tone, powered by strong
5d agoTNXP
Tonix Pharmaceuticals price target lowered to $14 from $26 at Raymond JamesRaymond James lowered the firm’s price target on Tonix Pharmaceuticals (TNXP) to $14 from $26 and keeps a Strong Buy rating on the shares. Tonmya sales rose 37% quarter-over-quarter to
5d agoTNXP
Tonix Pharmaceuticals reports Q3 EPS ($2.89), consensus ($2.24)Reports Q3 revenue $17.23M, consensus $16.32M. “We delivered another strong quarter for TONMYA, with net sales up 37% over the second quarter,” said Seth Lederman, President and Chief Executive Officer
6d agoTNXP
TNXP Upcoming Earnings Report: What to Expect?Tonix Pharmaceuticals (TNXP) is scheduled to report 3rd quarter earnings on 11/09/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Tonix Pharmaceuticals to post earnings of -$2.39
1w agoTNXP
Tonix Pharmaceuticals presents data from RELIEF, RESILIENT studies of TonmyaTonix Pharmaceuticals (TNXP) presented data from an analysis of the Phase 3 RELIEF and RESILIENT studies of Tonmya for the treatment of fibromyalgia in adults demonstrating outcomes as measured by
2w agoTNXP
Tonix Pharmaceuticals initiated with a Buy at CanaccordCanaccord analyst Gary Nachman initiated coverage of Tonix Pharmaceuticals (TNXP) with a Buy rating and $18 price target Tonix has been executing well with Tonmya for fibromyalgia, which was recently
2w agoTNXP
Tonix Pharmaceuticals price target lowered to $26 from $27 at Raymond JamesRaymond James analyst Tiago Fauth lowered the firm’s price target on Tonix Pharmaceuticals (TNXP) to $26 from $27 and keeps a Strong Buy rating on the shares. 2026 revenue estimates
3w agoTNXP
Recent Analysts Ratings of Custom Stocks
Most Recent Earnings of Custom Stocks
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| TNXP | Mar 15, 2027TBA | $58.49M | $-2.48 | $20.30M | 0.01 | -0.24 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
- Comprehensive Analysis: Compare up to 40 stocks with detailed metrics including price, market cap, P/E ratio, dividend yield, and more.
- Analyst Ratings: View consensus ratings from top Wall Street analysts and their price targets for each stock.
- Performance Tracking: Analyze historical performance with interactive charts showing 3-month, 6-month, 1-year, YTD, 3-year, and 5-year returns.
- Dividend Information: Evaluate dividend yield, payout ratio, and dividend growth for income-focused investors.
- Earnings Data: Compare earnings per share (EPS), revenue growth, and profitability metrics across companies.
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
All Stock Comparison Categories
- AAPL vs. MSFT (Apple vs. Microsoft)
- AMZN vs. GOOGL
- GOOGL vs. META (Alphabet vs. Meta)
- AAPL vs. NVDA (Apple vs. Nvidia)
- AMZN vs. WMT (Amazon vs. Walmart)
- AMD vs. INTC (AMD vs. Intel)
- AVGO vs. QCOM (Broadcom vs. Qualcomm)
- NVDA vs. TSM (Nvidia vs. Taiwan Semi)
- TSLA vs. RIVN (Tesla vs. Rivian)
- F vs. GM (Ford vs. General Motors)
- TSLA vs. LCID (Tesla vs. Lucid)
- V vs. MA (Visa vs. Mastercard)
- JPM vs. BAC (JPMorgan vs. Bank of America)
- PYPL vs. XYZ (PayPal vs. Block)
- HD vs. LOW (Home Depot vs. Lowe's)
- KO vs. PEP (Coca-Cola vs. PepsiCo
- COST vs. WMT (Costco vs. Walmart)
- NVDA vs. AMD vs. INTC (Chip Giants)
- MSFT vs. GOOGL vs. AMZN (Cloud Wars)
- TSLA vs. F vs. GM (Auto Wars)
- V vs. MA vs. AXP (Credit Cards)
- Quantum Computing Stocks
- Dividend Stocks
- Magnificent 7 Stocks
- Nuclear Stocks
- Oil Stocks
- Tech Stocks
- Blue Chip Stocks
- Energy Stocks
- Bank Stocks
- Gold Stocks
- Growth Stocks
- Bitcoin Stocks
- Meme Stocks
- Biotech Stocks
- Chinese Stocks
- Artificial Intelligence Stocks
- Cannabis Stocks
- Healthcare Stocks
- Value Stocks
- Airline Stocks
- Cybersecurity Stocks
- OpenAI Stocks
- Solar Stocks
- ChatGPT Stocks
- FAANG Stocks
- Green Energy Stocks
- Large Cap Stocks
- Utility Stocks
- Chip Stocks
- Blockchain Stocks
- Social Media Stocks
- Cryptocurrency Stocks
- Electric Vehicle Stocks
- Japanese Stocks
- Casino Stocks
- Metaverse Stocks
- Highest PE Ratio Stocks
- Mega Cap Stocks
- Hotel Stocks
- Green Hydrogen Stocks
- 5g Stocks
- Aerospace and Defense Stocks
- Batmmaan Stocks
- WallStreetBets Stocks
- Virtual Reality Stocks
- Cloud & Storage Stocks
- Lowest P/E Ratio Stocks
- Adtech Stocks
- Biotech & Longevity Plays
- Nuclear Energy Revival Stock
- Onshoring & Rare Earths Supply Stocks
- Popular BDC Stocks
- Private Credit & Fintech Risers
- Quantum Computing Innovators Stocks
- Robotics & Autonomous Systems Stocks
- Beer & Beverage Stocks
- International Value Diversifiers Stocks
- AI Data Center Pivot Miners
- AI Data Center Power Stocks
- Big Oil SAF Refiners (Biofuels)
- Data Center & AI Infrastructure Stocks
- MSFT vs. META (Microsoft vs. Meta)
- Popular South Korean Stocks
- Situational Awareness Q1 Pivot
- Situational Awareness Solar & Battery Bets
- Situational Awareness Top 10 Holdings
- Sustainable Aviation Fuel (SAF) Pure-Plays
- Top Robotics Stocks (Medical, AI & Industrial)
- Top Silver Stocks
- Trump Tariff Risk Stocks (Retail & Tech)
- Trump Tariff Winners (Steel, Manufacturing & Auto)
- Venezuela Oil Recovery (Energy & Services)
- Venezuela Seized Assets (Consumer/Industrial)
Custom Stock - FAQ
Which Custom stocks have a "Strong Buy" analyst rating?
These Custom stocks currently have a "Strong Buy" analyst rating consensus: Tonix Pharma - Strong Buy, based on 4 analyst ratings, 4 Buy, 0 Hold, and 0 Sell.
Are Custom stocks overpriced?
Tonix Pharma's stock price is currently $3.01, and its average 12-month price target is N/A.
Which Custom stocks pay dividends?
Tonix Pharma does not currently pay dividends.